Summit Therapeutics Inc. cash flow statement

In fiscal 2024, Summit Therapeutics Inc.'s operations generated −$142m of cash; it spent $139,000 on capital projects, leaving free cash flow of −$142m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Summit Therapeutics Inc.: cash flow statement, annual
Fiscal year	2016Jan 2016	2017Jan 2017	2018Jan 2018	2019Jan 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024
Cash from operations	−26	16	−19	−35	−48	−73	−42	−77	−142
Depreciation and amortisation	—	—	—	0	0	0	0	0	0
Stock-based pay	2	2	2	6	2	13	12	14	51
Capital spending	0	0	0	0	0	0	1	0	0
Free cash flow	−26	16	−19	−35	−49	−73	−42	−77	−142
Free cash flow after stock pay	−28	14	−21	−42	−50	−86	−54	−91	−193
Dividends paid	—	—	—	0	0	—	—	—	—
Shares issued	—	—	—	46	50	75	100	105	—

US$ millions unless shown otherwise. Fiscal quarters.

Summit Therapeutics Inc.: cash flow statement, quarterly
Quarter	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q3Sept 2024	2024 Q4Dec 2024
Cash from operations	−9	5	−13	−29	−15	−19	−30	−49
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	3	3	3	2	1	9	19	11
Capital spending	−0	−0	0	0	0	0	0	0
Free cash flow	−9	5	−13	−29	−15	−19	−30	−49
Free cash flow after stock pay	−11	3	−16	−31	−16	−28	−50	−60
Shares issued	100	0	105	0	0	0	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Summit Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Summit Therapeutics Inc.